Immunome (IMNM) Competitors $8.06 +0.06 (+0.75%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$7.99 -0.07 (-0.87%) As of 05/16/2025 06:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMNM vs. XENE, MOR, PTGX, MLTX, HCM, IMVT, ACAD, MTSR, APLS, and ALVOShould you be buying Immunome stock or one of its competitors? The main competitors of Immunome include Xenon Pharmaceuticals (XENE), MorphoSys (MOR), Protagonist Therapeutics (PTGX), MoonLake Immunotherapeutics (MLTX), HUTCHMED (HCM), Immunovant (IMVT), ACADIA Pharmaceuticals (ACAD), Metsera (MTSR), Apellis Pharmaceuticals (APLS), and Alvotech (ALVO). These companies are all part of the "pharmaceutical products" industry. Immunome vs. Xenon Pharmaceuticals MorphoSys Protagonist Therapeutics MoonLake Immunotherapeutics HUTCHMED Immunovant ACADIA Pharmaceuticals Metsera Apellis Pharmaceuticals Alvotech Xenon Pharmaceuticals (NASDAQ:XENE) and Immunome (NASDAQ:IMNM) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, media sentiment, dividends, earnings, community ranking and risk. Which has preferable earnings and valuation, XENE or IMNM? Immunome has lower revenue, but higher earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXenon Pharmaceuticals$9.43M246.03-$182.39M-$3.02-10.03Immunome$9.04M77.57-$106.81M-$3.18-2.53 Is XENE or IMNM more profitable? Xenon Pharmaceuticals has a net margin of 0.00% compared to Immunome's net margin of -3,014.59%. Xenon Pharmaceuticals' return on equity of -24.69% beat Immunome's return on equity.Company Net Margins Return on Equity Return on Assets Xenon PharmaceuticalsN/A -24.69% -23.68% Immunome -3,014.59%-48.63%-41.62% Do insiders and institutionals have more ownership in XENE or IMNM? 95.4% of Xenon Pharmaceuticals shares are held by institutional investors. Comparatively, 44.6% of Immunome shares are held by institutional investors. 5.5% of Xenon Pharmaceuticals shares are held by company insiders. Comparatively, 8.6% of Immunome shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Do analysts prefer XENE or IMNM? Xenon Pharmaceuticals currently has a consensus target price of $54.82, indicating a potential upside of 80.98%. Immunome has a consensus target price of $23.33, indicating a potential upside of 189.50%. Given Immunome's higher possible upside, analysts plainly believe Immunome is more favorable than Xenon Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xenon Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 3.00Immunome 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, XENE or IMNM? Xenon Pharmaceuticals has a beta of 1.21, suggesting that its stock price is 21% more volatile than the S&P 500. Comparatively, Immunome has a beta of 2, suggesting that its stock price is 100% more volatile than the S&P 500. Does the media refer more to XENE or IMNM? In the previous week, Xenon Pharmaceuticals had 37 more articles in the media than Immunome. MarketBeat recorded 48 mentions for Xenon Pharmaceuticals and 11 mentions for Immunome. Immunome's average media sentiment score of 0.91 beat Xenon Pharmaceuticals' score of 0.60 indicating that Immunome is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xenon Pharmaceuticals 12 Very Positive mention(s) 3 Positive mention(s) 10 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Positive Immunome 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Does the MarketBeat Community prefer XENE or IMNM? Xenon Pharmaceuticals received 393 more outperform votes than Immunome when rated by MarketBeat users. However, 78.00% of users gave Immunome an outperform vote while only 69.90% of users gave Xenon Pharmaceuticals an outperform vote. CompanyUnderperformOutperformXenon PharmaceuticalsOutperform Votes43269.90% Underperform Votes18630.10% ImmunomeOutperform Votes3978.00% Underperform Votes1122.00% SummaryXenon Pharmaceuticals beats Immunome on 10 of the 17 factors compared between the two stocks. Get Immunome News Delivered to You Automatically Sign up to receive the latest news and ratings for IMNM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMNM vs. The Competition Export to ExcelMetricImmunomePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$701.32M$6.43B$5.35B$8.51BDividend YieldN/A2.66%4.95%4.13%P/E Ratio-0.999.1126.8519.96Price / Sales77.57247.13389.69119.17Price / CashN/A65.8538.2534.62Price / Book2.916.446.764.59Net Income-$106.81M$143.46M$3.23B$248.34M7 Day Performance8.04%4.42%4.86%5.14%1 Month Performance1.90%7.87%9.88%13.64%1 Year Performance-41.72%-5.45%14.64%6.58% Immunome Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMNMImmunome2.6637 of 5 stars$8.06+0.8%$23.33+189.5%-44.0%$701.32M$9.04M-0.9940News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionXENEXenon Pharmaceuticals2.5163 of 5 stars$37.54-1.9%$56.78+51.2%-24.9%$2.88B$9.43M-13.31210Trending NewsEarnings ReportAnalyst ForecastOptions VolumeAnalyst RevisionMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730PTGXProtagonist Therapeutics3.4605 of 5 stars$44.28-2.7%$65.44+47.8%+39.3%$2.74B$434.43M16.65120Positive NewsMLTXMoonLake Immunotherapeutics3.1929 of 5 stars$41.90-1.0%$80.50+92.1%-7.9%$2.68BN/A-32.482Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionHCMHUTCHMED2.25 of 5 stars$15.12+0.8%$19.00+25.7%-36.1%$2.64B$630.20M0.001,760Positive NewsAnalyst DowngradeIMVTImmunovant2.6326 of 5 stars$15.22-3.7%$38.33+151.9%-54.1%$2.59BN/A-5.81120News CoveragePositive NewsACADACADIA Pharmaceuticals3.1828 of 5 stars$15.14+1.5%$23.87+57.6%+49.9%$2.53B$957.80M19.41510Trending NewsGap UpMTSRMetseraN/A$23.98-6.5%$47.00+96.0%N/A$2.52BN/A0.0081Earnings ReportAPLSApellis Pharmaceuticals4.1291 of 5 stars$19.98-1.8%$45.28+126.6%-58.5%$2.51B$781.37M-9.84770Analyst ForecastGap UpALVOAlvotech1.8471 of 5 stars$8.33+1.3%$18.00+116.1%-22.5%$2.48B$489.68M-4.504News CoverageUpcoming Earnings Related Companies and Tools Related Companies XENE Competitors MOR Competitors PTGX Competitors MLTX Competitors HCM Competitors IMVT Competitors ACAD Competitors MTSR Competitors APLS Competitors ALVO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMNM) was last updated on 5/17/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredWashington Is Broke—and Eyeing Your Savings NextWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunome, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunome With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
